Rofecoxib

162011-90-7

C17H14O4S

DMSO : 33.33 mg/mL (106.02 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble)

Immunology/Inflammation

Rofecoxib is a potent, specific and orally active COX-2 inhibitor, with IC₅₀s of 26 and 18 nM for human COX-2 in human osteosarcoma cells and Chinese hamster ovary cells, with a 1000-fold selectivity for COX-2 over human COX-1 (IC₅₀ > 50 uM in U937 cells and > 15 uM in Chinese hamster ovary cells). IC50 & Target: IC50: 26 nM (Human COX-2, in human osteosarcoma cells), 18 nM (Human COX-2, in Chinese hamster ovary cells), >50 uM (Human COX-1, in U937 cells), >15 uM (Human COX-1, in Chinese hamster ovary cells)^[1] In Vitro: Rofecoxib (MK-0966) is a potent and orally active inhibitor of COX-2, with IC₅₀s of 26 and 18 nM for human COX-2 in human osteosarcoma cells and Chinese hamster ovary cells, with a 1000-fold selectivity for COX-2 over COX-1 (IC₅₀ >50 uM in U937 cells and >15 uM in Chinese hamster ovary cells). Rofecoxib time dependently inhibits purified human recombinant COX-2 (IC₅₀=0.34 uM) but suppresses purified human COX-1 in a non-time-dependent manner that can only be observed at a very low substrate concentration (IC₅₀=26 uM at 0.1 uM arachidonic acid concentration). Rofecoxib selectively inhibits lipopolysaccharide-induced, COX-2-derived PGE(2) synthesis with an IC₅₀ value of 0.53 +/- 0.02 uM compared with an IC₅₀ value of 18.8 +/- 0.9 uM for the inhibition of COX-1-derived thromboxane B(2) synthesis after blood coagulation^[1]. Rofecoxib (36 uM) causes a cell proliferation of 68% in MPP89, of 58% in Ist-Mes-1 and 40% in Ist-Mes-2. MSTO-211H and NCI-H2452 treated with 36 uM of Rofecoxib have a survival of 97% and 90% respectively. Rofecoxib (36 uM) decreases COX-2 and mRNA levels in Ist-Mes-1, Ist-Mes-2 and MPP89 cell lines^[3]. In Vivo: Rofecoxib potently inhibits carrageenan-induced paw edema (ID₅₀=1.5 mg/kg), carrageenan-induced paw hyperalgesia (ID₅₀=1.0 mg/kg), lipopolysaccharide-induced pyresis (ID₅₀=0.24 mg/kg), and adjuvant-induced arthritis (ID₅₀=0.74 mg/kg/day) in rodent models. Rofecoxib also protects adjuvant-induced destruction of cartilage and bone structures in rats. In a ⁵¹Cr excretion assay for detection of gastrointestinal integrity in either rats or squirrel monkeys, rofecoxib shows no effect at doses up to 200 mg/kg/day for 5 days^[1]. Rofecoxib (15 mg/kg, i.p.) reduces the blood vessels attached to the internal limiting membrane (ILM) in mice. COX-2 and VEGF protein expressions, COX-2 mRNA and VEGF mRNA are also significantly decreased by Rofecoxib in ROP mice^[2].